spacer
home > ict > autumn 2016 > get involved
PUBLICATIONS
International Clinical Trials

Get Involved

Several studies have shown that applications of mHealth in healthcare settings have improved medication and procedural compliance (1); however, little research has been conducted on the effect of mHealth on clinical trial adherence and patient retention.

Clinical Ink piloted an mHealth sub-study with 30 subjects using a hybrid bring-your-own-device (BYOD)/provisioned device model, and results have indicated a low 6% subject dropout rate; a high average study procedure compliance of 84%; and high data quality. These data suggest that mHealth has an impact on reducing subject dropout rates, potentially improving protocol adherence and changing patient behaviour.

Research has shown that mHealth significantly enhances medication adherence, reduces non-adherence related adverse effects, and is accepted in healthcare in various geographic settings and among diverse demographic groups (1). Studies have also demonstrated that mHealth improves both recruitment and enrolment in clinical trials (2,3). Considering this with data showing nearly 43% of the global population and 68% of US adults owning a smartphone in 2015, advancing a BYOD approach (such as apps on a patient’s smartphone) in mHealth is inevitable (4,5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kyle Hogan is eClinical Solutions Director with Clinical Ink, and is responsible for the strategic alignment of the company’s native mobile application for clinical trials. Kyle has delivered technical solutions for complex business challenges since the 1990s, and has more than nine years of experience in clinical trials.
spacer
Kyle Hogan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement